Charles River Laboratories International (NYSE:CRL) Sets New 1-Year High – Here’s Why

Charles River Laboratories International, Inc. (NYSE:CRL)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as $242.73 and last traded at $240.7830, with a volume of 1257880 shares changing hands. The stock had previously closed at $224.30.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Finally, Barclays increased their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $220.75.

Charles River Laboratories International Stock Performance

The company has a market cap of $11.60 billion, a P/E ratio of -64.04, a price-to-earnings-growth ratio of 2.50 and a beta of 1.40. The business has a 50 day moving average price of $202.05 and a two-hundred day moving average price of $187.59. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.Charles River Laboratories International’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the company earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Insider Activity

In other news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director owned 31,596 shares in the company, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after acquiring an additional 47,432 shares during the last quarter. Invesco Ltd. increased its position in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the period. State Street Corp raised its stake in shares of Charles River Laboratories International by 2.2% during the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after acquiring an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after acquiring an additional 210,260 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after purchasing an additional 9,756 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.